866-997-4948(US-Canada Toll Free)

Hepatocellular Carcinoma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : May 2013

Category :

Oncology

No. of Pages : 542 Pages


Global Markets Directs, \'Hepatocellular Carcinoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatocellular Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma. 

Hepatocellular Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hepatocellular Carcinoma.
  • A review of the Hepatocellular Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hepatocellular Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 6
Hepatocellular Carcinoma Overview 7
Therapeutics Development 8
Hepatocellular Carcinoma Therapeutics under Development by Companies 10
Hepatocellular Carcinoma Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 19
Mid Clinical Stage Products 20
Early Clinical Stage Products 21
Discovery and Pre-Clinical Stage Products 22
Hepatocellular Carcinoma Therapeutics - Products under Development by Companies 23
Hepatocellular Carcinoma Therapeutics - Products under Investigation by Universities/Institutes 30
Companies Involved in Hepatocellular Carcinoma Therapeutics Development 31
Hepatocellular Carcinoma - Therapeutics Assessment 109
Drug Profiles 117
Hepatocellular Carcinoma Therapeutics - Drug Profile Updates 387
Hepatocellular Carcinoma Therapeutics - Discontinued Products 513
Hepatocellular Carcinoma Therapeutics - Dormant Products 514
Hepatocellular Carcinoma - Product Development Milestones 518

Appendix 526

List of Table


Number of Products Under Development for Hepatocellular Carcinoma, H1 2013 23
Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H1 2013 24
Number of Products under Development by Companies, H1 2013 26
Number of Products under Investigation by Universities/Institutes, H1 2013 33
Comparative Analysis by Late Stage Development, H1 2013 34
Comparative Analysis by Mid Clinical Stage Development, H1 2013 35
Comparative Analysis by Early Clinical Stage Development, H1 2013 36
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 37
Products under Development by Companies, H1 2013 38
Products under Investigation by Universities/Institutes, H1 2013 45
Bristol-Myers Squibb Company, H1 2013 46
Biocompatibles International plc, H1 2013 47
Boehringer Ingelheim GmbH, H1 2013 48
F. Hoffmann-La Roche Ltd., H1 2013 49
Celsion Corporation, H1 2013 50
Biogen Idec Inc., H1 2013 51
AstraZeneca PLC, H1 2013 52
Eli Lilly and Company, H1 2013 53
GlaxoSmithKline plc, H1 2013 54
MedImmune LLC, H1 2013 55
Daiichi Sankyo Company, Ltd, H1 2013 56
Takeda Pharmaceutical Company Limited, H1 2013 58
Delcath Systems, Inc., H1 2013 59
Light Sciences Oncology, Inc., H1 2013 60
ZIOPHARM Oncology, Inc., H1 2013 61
Novartis AG, H1 2013 62
Eisai Co., Ltd., H1 2013 63
Kowa Company, Ltd., H1 2013 64
MDRNA, Inc., H1 2013 65
Ono Pharmaceutical Co., Ltd., H1 2013 66
Pfizer Inc., H1 2013 67
SuperGen, Inc., H1 2013 68
Taiho Pharmaceutical Co., Ltd., H1 2013 69
Exelixis, Inc., H1 2013 70
Bayer AG, H1 2013 71
4SC AG, H1 2013 72
Active Biotech AB, H1 2013 73
IMMUNOMEDICS, INC, H1 2013 74
Ligand Pharmaceuticals Incorporated, H1 2013 76
MultiCell Technologies, Inc., H1 2013 77
NexMed, Inc., H1 2013 78
Nymox Pharmaceutical Corporation, H1 2013 79
Cleveland BioLabs, Inc., H1 2013 80
ARQULE, INC, H1 2013 82
Alnylam Pharmaceuticals, Inc, H1 2013 83
BTG International Ltd, H1 2013 84
TopoTarget A/S, H1 2013 85
Transgene SA, H1 2013 86
Senesco Technologies, Inc., H1 2013 87
Immuron Limited, H1 2013 88
Progen Pharmaceuticals Limited, H1 2013 89
Innocell Corporation, H1 2013 90
Threshold Pharmaceuticals, Inc., H1 2013 91
Provectus Pharmaceuticals, Inc., H1 2013 92
Synta Pharmaceuticals Corp., H1 2013 93
BioAlliance Pharma SA, H1 2013 94
Simcere Pharmaceutical Group, H1 2013 95
Raptor Pharmaceuticals Corp., H1 2013 96
Dicerna Pharmaceuticals, Inc., H1 2013 97
Sunway Biotech Co.,Ltd, H1 2013 98
Digna Biotech, S.L., H1 2013 99
Nerviano Medical Sciences S.r.l., H1 2013 101
Provecs Medical GmbH, H1 2013 104
GenSpera, Inc., H1 2013 105
Mondobiotech Holding AG, H1 2013 106
Jennerex Biotherapeutics, Inc., H1 2013 107
AndroScience Corporation, H1 2013 108
Onconova Therapeutics, Inc, H1 2013 109
MolMed S.p.A., H1 2013 110
Mirna Therapeutics, Inc., H1 2013 111
Omeros Corporation, H1 2013 112
Taiwan Liposome Company, H1 2013 113
CureTech Ltd., H1 2013 114
Vicus Therapeutics, LLC, H1 2013 115
TRACON Pharmaceuticals, Inc., H1 2013 116
KAHR medical Ltd., H1 2013 117
Regulus Therapeutics Inc., H1 2013 118
Galaxy Biotech, LLC, H1 2013 119
KAEL-GemVax, H1 2013 121
Therapure Biopharma Inc., H1 2013 122
Polaris Group, H1 2013 123
Assessment by Monotherapy Products, H1 2013 124
Assessment by Combination Products, H1 2013 125
Assessment by Stage and Route of Administration, H1 2013 128
Assessment by Stage and Molecule Type, H1 2013 131
Hepatocellular Carcinoma Therapeutics - Drug Profile Updates 402
Hepatocellular Carcinoma Therapeutics - Discontinued Products 528
Hepatocellular Carcinoma Therapeutics - Dormant Products 529

List of Chart


Number of Products under Development for Hepatocellular Carcinoma, H1 2013 23
Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H1 2013 24
Products under Development by Companies, H1 2013 25
Products under Investigation by Universities/Institutes, H1 2013 32
Late Stage Products, H1 2013 34
Mid Clinical Stage Products, H1 2013 35
Early Clinical Stage Products, H1 2013 36
Discovery and Pre-Clinical Stage Products, H1 2013 37
Assessment by Monotherapy Products, H1 2013 124
Assessment by Combination Products, H1 2013 125
Assessment by Route of Administration, H1 2013 126
Assessment by Stage and Route of Administration, H1 2013 127
Assessment by Molecule Type, H1 2013 129
Assessment by Stage and Molecule Type, H1 2013 130

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *